CMEA Ventures and InterWest Partners have led an $8.8 million A round for Arcion Therapeutics. Arcion has been developing ARC-4558, a topical gel to treat moderate and severe pain caused by diabetic neuropathy. Arcion also has gels in development for other pain indications, looking to compete in the sector by offering a new therapy with fewer side effects.
- see this release for more